ICBCCS CSI Rare Metals Theme ETF (159671) rises 5.31%, with a total net inflow of 99.8999 million yuan over the past 4 trading days
NewTimeSpace (newtimespace.com) News, as of 14:06 on June 22, 2026, ICBCCS Rare Metals ETF (159671) rose 5.31%, with the latest price at 1.72 yuan. Over a longer time frame, as of June 18, 2026, the ETF accumulated a gain of 5.75% over the past week.
In terms of liquidity, ICBCCS Rare Metals ETF recorded an intraday turnover rate of 5.48% and a trading volume of 92.4602 million yuan. Over a longer time frame, as of June 18, the ETF's average daily trading volume over the past week reached 109 million yuan.
In terms of scale, the latest scale of ICBCCS Rare Metals ETF reached 1.647 billion yuan, hitting a one-month high and ranking 3/9 among comparable funds. (Data source: Wind)
In terms of shares, ICBCCS Rare Metals ETF experienced a significant increase of 21.00 million units in share count over the past week, with the new share increase ranking 2/9 among comparable funds. (Data source: Wind)
In terms of capital flows, the latest net inflow for ICBCCS Rare Metals ETF was 814,700 yuan. Over a longer time frame, within the past four trading days, there were three days of net inflow, attracting a total of 99.8999 million yuan, with an average daily net inflow of 24.9750 million yuan. (Data source: Wind)
Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of ICBCCS Rare Metals ETF reached 2.0482 million yuan, with the latest margin financing balance standing at 5.4245 million yuan. (Data source: Wind)
As of June 18, the net value of ICBCCS Rare Metals ETF rose by 158.68% over the past two years, ranking 250/2805 among equity index funds, placing it in the top 8.91%. From the perspective of return capability, as of June 18, 2026, since its inception, the ETF achieved a highest single-month return of 24.07%, a longest streak of consecutive up months of 6 months, a maximum cumulative gain during that streak of 81.09%, a ratio of up months to down months of 22/17, an average return of 7.84% in up months, and a probability of positive return after a 3-year holding period of 100.00%. As of June 18, 2026, the ETF's annualized excess return over its benchmark for the past three months was 3.98%, ranking in the top 2/4 among comparable funds.
As of June 18, 2026, the one-year Sharpe ratio of ICBCCS Rare Metals ETF was 2.59, ranking in the top 2/4 among comparable funds, indicating higher returns for the same level of risk.
In terms of drawdown, as of June 18, 2026, ICBCCS Rare Metals ETF recorded a drawdown of 0.19% relative to its benchmark since the beginning of the year, reflecting lower drawdown risk among comparable funds.
In terms of fees, ICBCCS Rare Metals ETF has a management fee rate of 0.45% and a custodian fee rate of 0.07%, placing its fee structure at a relatively low level among comparable funds.
In terms of tracking accuracy, as of June 18, 2026, the two-year tracking error of ICBCCS Rare Metals ETF was 0.033%, achieving relatively high tracking accuracy among comparable funds.
ICBCCS Rare Metals ETF closely tracks the CSI Rare Metals Theme Index. The CSI Rare Metals Theme Index selects no more than 50 listed company securities whose businesses involve rare metal mining, smelting, and processing as index constituents, in order to reflect the overall performance of the securities of listed companies in the rare metals theme.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Hengrui Medicine (01276.HK): Marketing Authorization Application for Relugolix Tablets Accepted by EMA
- Regina Miracle International (02199.HK): Positive Profit Alert, Annual Net Profit Expected to Rise by No Less Than 45%
- Shandong Xinhua Pharmaceutical Company Limited (00719.HK): LXH-2103 Injection Approved for Clinical Trials
- CARSGEN-B(02171.HK): Kailimei® Secures NMPA Marketing Approval, the World’s First CAR-T Cell Therapy for Solid Tumors
- ChinaAMC Hang Seng Hong Kong Biotech Index ETF (03069.HK) Falls 0.66%, Turnover Reaches HKD 61.6949 Million